Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep-Oct;25(5):897-901.
doi: 10.4103/aian.aian_1127_21. Epub 2022 Jul 14.

Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study

Nikita Dhar  1 , Mritunjai Kumar  1 , Ashutosh Tiwari  1 , Ishita Desai  1 , Govind Madhaw  1   2 , Niraj Kumar  1
Affiliations

Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study

Nikita Dhar et al. Ann Indian Acad Neurol. 2022 Sep-Oct.

Abstract

Objective: To compare the efficacy and safety of thrombolysis using Tenecteplase (TNK) versus alteplase in acute ischaemic stroke (AIS) patients within 4.5-hour window period.

Methods: This retrospective study involved the collection of data from consecutive AIS patients who underwent thrombolysis in the Department of Neurology at a tertiary care university hospital, between May 2018 to January 2021. Data including clinical history, neurological assessment using modified Rankin score (mRS), National Institutes of Health Stroke Scale (NIHSS), brain neuroimaging, treatment, and outcome details were collected. The primary efficacy outcome was the proportion of patients with good functional recovery (mRS of 0-2) at 90 days of follow-up.

Results: Total of 42 patients with AIS underwent thrombolysis, of which 19 received alteplase and 23 got TNK. The median (range) onset to door time [120 (20-210) versus 120 (30-210) minutes; P = 0.823] and median (range) onset to needle time [150 (60-255) versus 160 (50-240) minutes; P = 0.779] were comparable in both alteplase and TNK groups, respectively. The primary outcome of good functional recovery (mRS ≤2) at 3 months was observed in more than half the patients in each group and was comparable (P = 0.701). Post-thrombolysis complications including cerebral haemorrhage (symptomatic or asymptomatic) were comparable between the two groups (31.6% vs 30.4%; P = 0.936), except a significantly higher proportion of patients on TNK required mechanical ventilation (10.5% v/s 43.5%; P = 0.019).

Conclusions: This study showed a comparable efficacy and safety profile of alteplase and TNK in thrombolysis of AIS throughout the 4.5 hours window period. Moreover, the ease of administration and better pharmacodynamic properties favors tenecteplase.

Keywords: Acute ischaemic stroke; alteplase; efficacy; safety; tenecteplase; thrombolysis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Donkor ES. Stroke in the 21st century:A snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat. 2018;2018:3238165. doi:10.1155/2018/3238165. - PMC - PubMed
    1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016:A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–80. - PMC - PubMed
    1. Smalling RW. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator. Eur Heart J. 1997;18((Suppl F)):F11–6. - PubMed
    1. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670–4. - PMC - PubMed
    1. Ramakrishnan TC, Kumaravelu S, Narayan SK, Buddha SS, Murali C, Majeed PHA, et al. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke:Results of two open-label, multicenter trials. Am J Cardiovascular Drugs. 2018;18:387–95. - PubMed